Literature DB >> 1971297

Recombinant IL-2 therapy reverses diminished granulomatous responsiveness in anti-L3T4-treated, Schistosoma mansoni-infected mice.

R C Mathew1, S Ragheb, D L Boros.   

Abstract

We have previously shown, that anti-L3T4 mAb treatment strongly suppressed granuloma formation in the liver, and IL-2 production in the spleen of Schistosoma mansoni-infected mice. In the present study the dynamics of IL-2 production was delineated during the infection, and the effect of rIL-2 treatment on granulomatous responsiveness was examined. IL-2 production in soluble egg Ag-stimulated spleen cells of mice was detectable at 6, peaked at 8 and waned by 20 wk of the infection. In contrast, Con A stimulus elicited high levels of IL-2 production by 8 wk which remained nearly unchanged throughout the infection. Administration of rIL-2 to acutely infected, anti-L3T4 mAb-treated, or chronically infected mice reversed the diminished or modulated granulomatous responses without restoring the ability for endogenous IL-2 production. Transfer of spleen cells of anti-L3T4 mAb-treated, chronically infected mice did not indicate a role for Ts cells in the impaired production of IL-2 in recipients. These data suggest that lack of IL-2 production can play an important role in the immunoregulation of the granulomatous response.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971297

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Regulation of granulomatous inflammation in experimental models of schistosomiasis.

Authors:  Abram B Stavitsky
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

2.  Schistosomal egg antigen-responsive CD8 T-cell population in Schistosoma mansoni-infected BALB/c mice.

Authors:  V Pancré; M Delacre; J Herno; C Auriault
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

3.  Dynamic analysis of splenic Th1 and Th2 lymphocyte functions in mice infected with Schistosoma japonicum.

Authors:  Y H Xu; J Macedonia; A Sher; E Pearce; A W Cheever
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

Review 4.  Schistosomiasis. Infection versus disease and hypersensitivity versus immunity.

Authors:  A W Cheever
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

5.  Utilization of fractionated soluble egg antigens reveals selectively modulated granulomatous and lymphokine responses during murine schistosomiasis mansoni.

Authors:  N W Lukacs; D L Boros
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

6.  T-lymphocyte responsiveness in murine schistosomiasis mansoni is dependent upon the adhesion molecules intercellular adhesion molecule-1, lymphocyte function-associated antigen-1, and very late antigen-4.

Authors:  J G Langley; D L Boros
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

7.  Schistosoma japonicum-infected mice show reduced hepatic fibrosis and eosinophilia and selective inhibition of interleukin-5 secretion by CD4+ cells after treatment with anti-interleukin-2 antibodies.

Authors:  A W Cheever; Y Xu; A Sher; F D Finkelman; T M Cox; J G Macedonia
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

8.  Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor.

Authors:  S W Chensue; K Warmington; J Ruth; P Lincoln; M C Kuo; S L Kunkel
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

9.  Two distinct pathological syndromes in male CBA/J inbred mice with chronic Schistosoma mansoni infections.

Authors:  G S Henderson; N A Nix; M A Montesano; D Gold; G L Freeman; T L McCurley; D G Colley
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

10.  Endogenous IL-10 regulates IFN-gamma and IL-5 cytokine production and the granulomatous response in Schistosomiasis mansoni-infected mice.

Authors:  D L Boros; J R Whitfield
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.